Introduction: The immunosuppressive therapy with everolimus (ERL) after heart transplantation is characterized by a narrow therapeutic window and a substantial variability in dose requirement. Factors explaining this variability are largely unknown.
Objectives: Our aim was to evaluate factors affecting ERL metabolism and to identify novel metabolites associated with the individual ERL dose requirement to elucidate mechanisms underlying ERL dose response variability.
Method: We used liquid chromatography coupled with mass spectrometry for quantification of ERL metabolites in 41 heart transplant patients and evaluated the effect of clinical and genetic factors on ERL pharmacokinetics. Non-targeted plasma metabolic profiling by ultra-performance liquid chromatography and high resolution quadrupole-time-of-flight mass spectrometry was used to identify novel metabolites associated with ERL dose requirement.
Results: The determination of ERL metabolites revealed differences in metabolite patterns that were independent from clinical or genetic factors. Whereas higher ERL dose requirement was associated with co-administration of sodium-mycophenolic acid and the CYP3A5 expressor genotype, lower dose was required for patients receiving vitamin K antagonists. Global metabolic profiling revealed several novel metabolites associated with ERL dose requirement. One of them was identified as lysophosphatidylcholine (lysoPC) (16:0/0:0). Subsequent targeted analysis revealed that high levels of several lysoPCs were significantly associated with higher ERL dose requirement.
Conclusion: For the first time, this study describes distinct ERL metabolite patterns in heart transplant patients and detected potentially new drug-drug interactions. The global metabolic profiling facilitated the discovery of novel metabolites associated with ERL dose requirement that might represent new clinically valuable biomarkers to guide ERL therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11306-017-1294-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Alternative Approach for Evaluating Induced and Contact Currents for Compliance with Their Exposure Limits (100 kHz to 110 MHz) in IEEE Std C95.1-2019.
Health Phys
February 2025
4455 Worden Way, Oakland, CA 94619.
The Institute of Electrical and Electronics Engineers establishes exposure reference levels ( ERL s) for electric fields ( E -fields) (0-300 GHz) and both induced ( I IND ) and contact currents ( I SC ) (<110 MHz) in its standard, IEEE Std C95.1™-2019 (IEEE C95.1).
View Article and Find Full Text PDFEffects of physical therapy modalities for motor function, functional recovery, and post-stroke complications in patients with severe stroke: a systematic review update.
Syst Rev
October 2024
Ernst-Abbe-Hochschule Jena-University of Applied Science, Carl-Zeiß-Promenade 2, 07745 Jena, Germany.
Background: Physical therapy interventions play a crucial role in the daily care of patients recovering from severe stroke. However, the efficacy of these interventions and associated modalities, including duration, intensity, and frequency, have not been fully elucidated. In 2020, a systematic review reported the beneficial effects of physical therapy for patients with severe stroke but did not assess therapeutic modalities.
View Article and Find Full Text PDFAssociation between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants.
BMC Infect Dis
September 2024
Université de Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux, F-33000, France.
Article Synopsis
- * Using a cohort of over 3,600 participants, researchers measured levels of specific antibodies and assessed SARS-CoV-2 infection outcomes over the next six months.
- * Results showed that higher anti-Spike IgG antibody levels correlated with reduced infection risk in the control group, but this was not the case for individuals in specific patient populations.
Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach.
Pharmaceutics
July 2024
Department of Pharmaceutical Engineering and Technology, IIT (BHU), Varanasi 221005, India.
This study explored the combined administration of docetaxel (DOC) and erlotinib (ERL) using nanostructured lipid carriers (NLCs), with folic acid (FA) conjugation to enhance their synergistic anticancer efficacy against triple-negative breast cancer. NLCs were developed through hot melt homogenization-ultrasound dispersion, and optimized by a quality-by-design (QbD) approach using Plackett-Burman design and Box-Behnken design. Plots were generated based on maximum desirability.
View Article and Find Full Text PDFFunctionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer.
Eur J Pharm Biopharm
August 2024
Department of Pharmaceutical Engineering & Technology, IIT (BHU), Varanasi 221005, India. Electronic address:
The goal of the study was to fabricate folic acid functionalized docetaxel (DOC)/erlotinib (ERL)-loaded solid lipid nanoparticles (SLNs) to synergistically increase the anticancer activity against triple-negative breast cancer. DOC/ERL-SLNs were prepared by the high shear homogenization - ultrasound dispersion method (0.1 % w/v for DOC, and 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!